GlassScriptPhysician profile
Sheena Patel
NPI 1932454709
$202,067.60
in general payments reported to CMS, 2019-2025
44 companies · $5,287 in 2025
The $5,287 reported for 2025 was more than what 98% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
See the full distribution for Psychiatric/Mental Health, Adult (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32K · 2022: $57K · 2023: $73K · 2024: $35K · 2025: $5,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Food and Beverage: $17K · Travel and Lodging: $17K · Consulting Fee: $3,774 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,830.00 |
| Food and Beverage | $16,755.90 |
| Travel and Lodging | $16,565.56 |
| Consulting Fee | $3,774.00 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $92,277.45 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $62,558.68 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $22,176.55 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $5,894.30 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $2,963.31 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,775.95 | 2021-2025 | Caplyta |
| Astellas Pharma US INC | $2,010.00 | 2023 | |
| Allergan, INC. | $1,821.37 | 2022 | |
| Neurocrine Biosciences, INC. | $1,580.38 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $1,281.61 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $1,185.30 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $924.55 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $609.32 | 2022-2025 | Auvelity, Sunosi |
| Biogen, INC. | $300.34 | 2021-2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $287.77 | 2021-2025 | Trintellix |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $274.47 | 2021-2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $262.16 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $257.51 | 2021-2022 | |
| Indivior INC. | $243.35 | 2021-2024 | Sublocade |
| Almatica Pharma LLC | $234.93 | 2021-2025 | Loreev Xr, Sertraline Hcl, Citalopram |
| Ironshore Pharmaceuticals INC. | $233.61 | 2023-2024 | Jornay Pm |
| Corium, LLC | $218.20 | 2023-2025 | Azstarys |
| Noven Therapeutics, LLC | $201.52 | 2021-2025 | Xelstrym, Secuado |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.99 | 2022-2023 | |
| Eisai INC. | $180.49 | 2021-2022 | |
| Neuronetics, INC. | $157.29 | 2023 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $132.38 | 2023-2024 | Quviviq |
| Davol INC. | $106.09 | 2024 | Phasix Mesh |
| Uswm, LLC | $102.78 | 2021-2023 | Lucemyra |
| Adlon Therapeutics L.P. | $95.45 | 2021 | |
| Bausch Health US, LLC | $71.36 | 2021-2022 | |
| Braeburn INC. | $61.95 | 2025 | Brixadi |
| Noven Pharmaceuticals, INC. | $57.90 | 2022-2023 | Xelstrym |
| Tris Pharma INC | $49.58 | 2024 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $44.33 | 2022-2025 | Rejoyn |
| Merck Sharp & Dohme LLC | $40.24 | 2021-2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $37.52 | 2021 | |
| Luye Pharma (USA) LTD. | $28.58 | 2025 | Erzofri Extended-Release |
| Avadel Cns Pharmaceuticals, LLC | $27.82 | 2025 | Lumryz |
| Sumitomo Pharma America, INC. | $27.04 | 2023 | Latuda |
| Orexo US, INC. | $22.81 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.65 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.60 | 2025 | Jornay Pm |
| Novo Nordisk INC | $16.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheena Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.